Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Pati… (NCT03038256) | Clinical Trial Compass
UnknownPhase 2
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial
China244 participantsStarted 2018-01-31
Plain-language summary
The purpose of this study was to evaluate the effect of concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX pre- a delayed TME compared with 6 cycles XELOX post- a Regular Timing TME in patients with high-risk rectal cancer defined by MRI.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age of 18-75 years;
✓. Histologically confirmed adenocarcinoma;
✓. The rectal adenocarcinoma 0-12cm from the anal margin on Magnetic resonance imaging (MRI) and/or rigid sigmoidoscopy;
✓. High risk of rectal cancer defined by high-resolution MRI: tumor invasion 5mm beyond the muscularis propria, or extramural vascular invasion, or circumferential resection margin unsafe, or the lower rectal cancer invades intersphincteric space, or rectal cancer invades the adjacent structures.
✓. Eastern Collaborative Oncology Group performance status score of 0 or 2
✓. Able and willing to give informed consent to participate.
Exclusion criteria
✕. Received preoperative chemoradiotherapy for rectal cancer before the recruitment of this study;
✕. Have metastatic disease (including non-regional lymph nodes metastases or resectable liver metastases);
✕. Other malignancies, non-adenocarcinoma rectal malignancies or rectal malignancies on the basis of inflammatory bowel disease;
✕. Emergency surgery due to bowel obstruction, perforation, bleeding, etc.;
✕. Abnormality of capecitabine absorption due to gastrointestinal disease e.g. short bowel syndrome, inflammation bowel disease, et al.;
✕
What they're measuring
1
Pathological complete response rate
Timeframe: up to 30days after total mesorectal excision
✕. Cardiac Disease：uncontrolled or symptomatic cardiac angina，or uncontrolled arrhythmias and hypertension, or severe congestive heart failure grade II or more based on New York Heart Association (NYHA); myocardial infarction within the past 12 months